Astellas Pharma (4503) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
8 Jul, 2026Executive summary
Achieved double-digit revenue growth (+10.2% YoY) and significant core operating profit increase (+48.6% YoY), driven by strong performance of strategic brands, especially PADCEV, IZERVAY, VYLOY, VEOZAH, and XTANDI, and cost optimization initiatives.
Full-year forecasts for revenue, core operating profit, and operating profit were revised upward, reflecting robust business performance and continued momentum.
Pipeline advanced with key regulatory approvals and positive clinical trial results for PADCEV, VYLOY, ASP3082, and ASP2138, supporting future growth.
Gross profit increased 9.0% year-over-year to ¥1,286.6 billion.
Financial highlights
Revenue for Q3 YTD FY2025 reached ¥1,601.3 billion, up 10.2% year-over-year; core operating profit rose to ¥442.1 billion (+48.6% YoY), with margin up to 27.6% (+7.1ppt YoY).
Operating profit was ¥333.9 billion, and net profit was ¥248 billion, both significantly higher year-over-year.
SG&A expenses decreased 1.0% year-over-year to ¥625.6 billion, aided by cost optimization and favorable FX impact; SG&A ratio improved by 2.7ppt YoY to 27.0%.
R&D expenses fell 12.9% year-over-year to ¥218.9 billion, reflecting cost optimization and lower clinical development costs; R&D ratio reduced to 13.7%.
Free cash flow surged to ¥310.8 billion (Q3 YTD), up from ¥7.0 billion YoY; cash and equivalents increased to ¥254.3 billion.
Outlook and guidance
Full-year FY2025 revenue forecast raised to ¥2,100 billion (+3.4% YoY); core operating profit forecast increased to ¥520 billion (+6.1% YoY), with margin expected to rise by 4.2ppt YoY to 24.8%.
Full basis profit forecast for FY2025 is ¥250 billion, up 38.9% year-over-year.
SG&A and R&D expenses expected to remain stable or decrease as a percentage of revenue.
Continued growth expected for strategic brands and further cost optimization targeted through FY2027.
No impairment indication as of Feb 2026.
Latest events from Astellas Pharma
- Raised FY2026 outlook supports a pivot to pipeline-led growth from FY2029.4503
Investor presentation - FY26 margin target pulled forward as pipeline-led growth builds beyond XTANDI.4503
Jefferies Global Healthcare Conference - Strategic Brand growth lifts FY2026 core operating profit guidance to ¥700bn.4503
Q2 2027 - Sustainability efforts and governance reforms are driving measurable enterprise value and innovation.4503
Sustainable Meeting 2024 - Record revenue and profit growth led by strategic brands, pipeline advances, and global expansion.4503
Q1 2027 - Pipeline-led growth, high-margin brands, and oncology innovation to drive record revenues.4503
Jefferies Global Healthcare Conference 2026 - Record revenue and profit growth driven by Strategic Brands and cost optimization, with strong FY2026 outlook.4503
Q4 2026 - Core operating profit surged 54.4% on 10.1% revenue growth and strong brand sales.4503
Q2 2026 - Q1 revenue up 26.2% year-on-year, driven by XTANDI and strategic brands, with strong profit growth.4503
Q1 2025